misleading statements

Schall Law Firm investigates Oddity Tech after 49% stock plunge following Q4 results. Probe examines whether investors were adequately informed of advertising partner risks.

Class action lawsuit filed against uniQure for allegedly making false statements about FDA approval status and BLA submission timelines, misleading investors.

Varonis Systems faces securities lawsuit alleging executives failed to disclose weakening renewal rates and overstated SaaS transition progress, leading to 48% stock decline and $3.8 billion market cap loss.

Corcept Therapeutics faces securities lawsuit alleging it misrepresented relacorilant's FDA approval prospects, causing stock to plunge 50% after regulatory rejection.

AMC faces class action lawsuit alleging it misled investors about Preferred Equity Unit rights, excluding APE holders from a 2023 dividend distribution through undisclosed technical loopholes.

Fermi Inc. faces securities class action over alleged false statements regarding Project Matador campus development and undisclosed single-tenant dependency risks.

Richtech Robotics faces class action lawsuit for allegedly misrepresenting Microsoft partnership. Stock fell 20.9% after Microsoft clarified the relationship wasn't a commercial partnership.

Inovio Pharmaceuticals faces class action lawsuit over alleged false statements regarding manufacturing defects and regulatory prospects after FDA rejected accelerated approval, causing 24% stock decline.

Agilon Health faces class action lawsuit over false 2025 financial guidance. Lead plaintiff deadline set for March 2, 2026; eligible investors urged to apply.

NuScale Power faces securities fraud lawsuit over alleged misrepresentations about its ENTRA1 Energy partnership. Stock fell 70% after November 2025 disclosures of $495M payment and $532M loss.

Plug Power faces securities fraud lawsuit over alleged false statements about DOE loan program. Stock declined after executive departures and suspended loan activities.

Four major companies face securities fraud lawsuits for misleading investors on AI spending, financial disclosures, and manufacturing claims. Investor filing deadlines approaching.

CoreWeave faces securities fraud lawsuit alleging false statements about operational capabilities and concealed business risks during 2025, following merger collapse and infrastructure delays.

Class action lawsuit filed against Navan alleging IPO disclosure failures on sales and marketing costs. Stock fell 64% from $25 to $9.01 since offering.

Corcept Therapeutics faces class action lawsuit for allegedly misleading statements about relacorilant's clinical evidence. FDA rejected the drug application, causing stock to plummet 50%.

Vistagen faces securities lawsuit over misleading trial disclosures. Investors must nominate lead plaintiff by March 16, 2026 deadline.

Richtech Robotics faces securities lawsuit after overstating Microsoft partnership, causing 30% stock surge followed by 20% decline when Microsoft clarified limited engagement.

Fermi Inc. faces securities lawsuit alleging IPO misrepresentations about AI data center demand and undisclosed tenant risks. Stock fell 59% after primary tenant's $150M funding agreement termination.

REGENXBIO faces class action lawsuit alleging executives made false statements about RGX-111 gene therapy's efficacy and safety, seeking shareholder damages.

PayPal faces securities lawsuit over allegedly false 2027 guidance and checkout platform claims. Investors who bought stock Feb 2025-Feb 2026 may seek compensation.